News
Lynozyfic (linvoseltamab) has been given accelerated approval by the US regulator for adults with relapsed or refractory ...
5d
Investor's Business Daily on MSNHeart Drug Stock Rockets 20% On Sales, Boosts Outlook; Regeneron Pharma's Global Partnership Strong TailwindKiniksa stock rocketed 20% after first-quarter results on April 29. The biotech stock then broke out of a cup base with a buy ...
Recent FDA decisions added new options for dermatologists involved in treating patients with psoriasis, bullous pemphigoid ...
In this video, Robert J. Smith, MD, discusses the many treatment options available to patients with atopic dermatitis.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult ...
The Business Research Company's The Specific Antiviral Drugs For COVID 19 Market Forecast To 2034 – For Business Leaders, Analysts, And Strategic Teams It will grow to $28.43 billion in 2029 at a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results